Lv41
710 积分 2022-12-01 加入
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
1个月前
已完结
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
2个月前
已完结
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
2个月前
已完结
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
2个月前
已完结
Endometriosis and Ovarian Cancer
2个月前
已完结
Review and prospect of CD146 research
2个月前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
3个月前
已完结
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
4个月前
已完结
Sunvozertinib monotherapy in EGFR tyrosine kinase Inhibitor-Resistant Non-Small cell lung cancer with EGFR mutations
4个月前
已完结
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
5个月前
已完结
皖公网安备34019202002308
